A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Solid Tumor
Unknown Primary
18 Years and older, Male and Female
2020-306-GLOB2 (primary)
NCI-2021-01982
Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and
preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
Objectives
HMPL-306 is a dual IDH1/2 inhibitor
This is a phase 1, open-label, multicenter study to evaluate the safety and tolerability of
HMPL-306 administered orally in the treatment of subjects with advanced or metastatic solid
tumors with IDH mutation. The study consists of 2 parts: Part 1 (dose escalation) and Part 2
(dose expansion). The dose escalation part will determine the MTD/RP2D. The dose expansion
part will administer the MTD/RP2D to mIDH-positive solid tumor malignancies including, but
not limited to, cholangiocarcinoma, skeletal chondrosarcoma, low-grade glioma, perioperative
low-grade glioma
Eligibility
- Key Inclusion Criteria:
Subjects are eligible for enrollment into this study if they meet any of the following
criteria (NOTE: This is not an exhaustive list):
- Subjects aged =18 years.
- ECOG performance status 0 or 1
- Subjects must have a documented IDH mutation per immunohistochemistry (IHC),
polymerase chain reaction (PCR), or next generation sequencing (NGS) testing of tumor
tissue.
- Subjects must have histologically or cytologically documented, advanced or metastatic
solid malignancy of any type that has recurred or progressed on available standard
treatment and for which no curative therapy exists.
Key Exclusion Criteria:
Subjects are not eligible for enrollment into this study if they meet any of the following
criteria (NOTE: This is not an exhaustive list):
- Subjects who received an investigational agent <14 days prior to their first day of
study drug administration
- Subjects who are pregnant or breastfeeding
- Subjects with an active severe infection, some treated infections and with an expected
or with an unexplained fever >38.3°C during screening visits or on their first day of
study drug administration.
- Subjects with some current or prior heart conditions
- Subjects taking medications that are known to prolong the QT interval may not be
eligible
- Subjects with immediately life-threatening, severe complications of leukemia such as
uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated
intravascular coagulation
- Some subjects with some current or prior gastrointestinal or liver diseases
- Subjects with inadequate organ function as defined by the protocol
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.